2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Inhibition of adult T‐cell leukemia cell proliferation by polymerized proanthocyanidin from blueberry leaves through JAK proteolysis

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          We have previously reported that the proanthocyanidin (PAC) fraction of blueberry leaf extract (BB‐PAC) inhibits the proliferation of HTLV‐1‐infected adult T‐cell leukemia (ATL) by inducing apoptosis. In the present study, we further analyzed the structure of BB‐PAC and elucidated the molecular mechanism underlying the inhibitory function of HTLV‐1‐infected and ATL cells. After hot water extraction with fractionation with methanol‐acetone, BB‐PAC was found to be concentrated in fractions 4 to 7 (Fr7). The strongest inhibition of ATL cell growth was observed with Fr7, which contained the highest BB‐PAC polymerization degree of 14. The basic structure of BB‐PAC is mainly B‐type bonds, with A‐type bonds (7.1%) and cinchonain I units as the terminal unit (6.1%). The molecular mechanism of cytotoxicity observed around Fr7 against ATL cells was the degradation of JAK1 to 3 and the dephosphorylation of STAT3/5, which occurs by proteasome‐dependent proteolysis, confirming that PAC directly binds to heat shock protein 90 (HSP90). JAK degradation was caused by proteasome‐dependent proteolysis, and we identified the direct binding of PAC to HSP90. In addition, the binding of cochaperone ATPase homolog 1 (AHA1) to HSP90, which is required for activation of the cofactor HSP90, was inhibited by BB‐PAC treatment. Therefore, BB‐PAC inhibited the formation of the HSP90/AHA1 complex and promoted the degradation of JAK protein due to HSP90 dysfunction. These results suggest that the highly polymerized PAC component from blueberry leaves has great potential as a preventive and therapeutic agent against HTLV‐1‐infected and ATL cells.

          Abstract

          Proanthocyanidins in blueberry leaves degrade JAK protein in adult T‐cell leukemia cells by inhibiting heat shock protein 90, and inhibit JAK/STAT signaling, causing cell death.

          Related collections

          Most cited references38

          • Record: found
          • Abstract: found
          • Article: not found

          Targeting the dynamic HSP90 complex in cancer.

          The molecular chaperone heat shock protein 90 (HSP90) has been used by cancer cells to facilitate the function of numerous oncoproteins, and it can be argued that cancer cells are 'addicted' to HSP90. However, although recent reports of the early clinical efficacy of HSP90 inhibitors are encouraging, the optimal use of HSP90-targeted therapeutics will depend on understanding the complexity of HSP90 regulation and the degree to which HSP90 participates in both neoplastic and normal cellular physiology.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found
            Is Open Access

            Proanthocyanidins: A comprehensive review

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Hsp90 cochaperone Aha1 downregulation rescues misfolding of CFTR in cystic fibrosis.

              The pathways that distinguish transport of folded and misfolded cargo through the exocytic (secretory) pathway of eukaryotic cells remain unknown. Using proteomics to assess global cystic fibrosis (CF) transmembrane conductance regulator (CFTR) protein interactions (the CFTR interactome), we show that Hsp90 cochaperones modulate Hsp90-dependent stability of CFTR protein folding in the endoplasmic reticulum (ER). Cell-surface rescue of the most common disease variant that is restricted to the ER, DeltaF508, can be initiated by partial siRNA silencing of the Hsp90 cochaperone ATPase regulator Aha1. We propose that failure of DeltaF508 to achieve an energetically favorable fold in response to the steady-state dynamics of the chaperone folding environment (the "chaperome") is responsible for the pathophysiology of CF. The activity of cargo-associated chaperome components may be a common mechanism regulating folding for ER exit, providing a general framework for correction of misfolding disease.
                Bookmark

                Author and article information

                Contributors
                kmorishi@med.miyazaki-u.ac.jp
                Journal
                Cancer Sci
                Cancer Sci
                10.1111/(ISSN)1349-7006
                CAS
                Cancer Science
                John Wiley and Sons Inc. (Hoboken )
                1347-9032
                1349-7006
                13 February 2022
                April 2022
                : 113
                : 4 ( doiID: 10.1111/cas.v113.4 )
                : 1406-1416
                Affiliations
                [ 1 ] Division of Tumor and Cellular Biochemistry Department of Medical Sciences University of Miyazaki Miyazaki Japan
                [ 2 ] Department of Applied Chemistry Faculty of Engineering University of Miyazaki Miyazaki Japan
                [ 3 ] Miyazaki Prefectural Food Research and Development Center Miyazaki Japan
                [ 4 ] Department of Biochemistry and Applied Biosciences Faculty of Agriculture University of Miyazaki Miyazaki Japan
                [ 5 ] Center for Collaborative Research and Community Cooperation University of Miyazaki Miyazaki Japan
                [ 6 ] Division of Hematology, Diabetes, and Endocrinology Department of Internal Medicine Faculty of Medicine University of Miyazaki Miyazaki Japan
                [ 7 ] Project for Advanced Medical Research and Development Project Research Division Frontier Science Research Center University of Miyazaki Miyazaki Japan
                Author notes
                [*] [* ] Correspondence

                Kazuhiro Morishita, Project for Advanced Medical Research and Development, Project Research Division, Frontier Science Research Center, University of Miyazaki, 5200 Kihara, Kiyotake, Miyazaki 889‐1692, Japan.

                Email: kmorishi@ 123456med.miyazaki-u.ac.jp

                Author information
                https://orcid.org/0000-0002-0679-5866
                https://orcid.org/0000-0002-2245-9950
                Article
                CAS15277
                10.1111/cas.15277
                8990289
                35100463
                34a77c84-038a-4410-8f09-addabc68ed72
                © 2022 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

                History
                : 27 December 2021
                : 06 August 2021
                : 19 January 2022
                Page count
                Figures: 5, Tables: 1, Pages: 11, Words: 6951
                Funding
                Funded by: Shinnihon Foundation of Advanced Medical Treatment Research
                Funded by: Takeda Science Foundation
                Funded by: Japan Society for the Promotion of Science
                Award ID: 17H03581
                Award ID: 18K07238
                Award ID: 21K07128
                Categories
                Original Article
                ORIGINAL ARTICLES
                Drug Discovery and Delivery
                Custom metadata
                2.0
                April 2022
                Converter:WILEY_ML3GV2_TO_JATSPMC version:6.1.3 mode:remove_FC converted:08.04.2022

                Oncology & Radiotherapy
                atl,blueberry leaf,hsp90,jak/stat,proanthocyanidin
                Oncology & Radiotherapy
                atl, blueberry leaf, hsp90, jak/stat, proanthocyanidin

                Comments

                Comment on this article